GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
11/05/2026 07:26
May 11 (Reuters) - GSK GSK.L on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical 1177.HK to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China. (Reporting by Prerna Bedi in Bengaluru) ((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up